The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients

Mol Cancer. 2022 May 19;21(1):117. doi: 10.1186/s12943-022-01590-0.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Circulating Tumor DNA* / genetics
  • Humans
  • Lung Neoplasms* / genetics
  • Mutation

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA